Lactobacillus Casei Shirota.
Lactobacillus Casei Shirota supplementation for targeted health support. Survives stomach acid and colonizes the intestine. Supports gut barrier function, modulates immune response, and may benefit mental health through gut-brain axis.
Reviewed March 2026
- Category
- Probiotic
What Lactobacillus Casei Shirota is, and what it does.
- Does it work
- One of the most researched probiotics ever. Nearly a century of safe use. The evidence base is impressive. The Yakult format is convenient and affordable.
- How much to take
- One Yakult bottle daily provides 6.5 billion live LcS. Studies used similar doses.
- Time to feel it
- Digestive changes usually show up across the first one to two weeks of daily intake. Bowel habit measures in trials were read over several weeks.
- The first dose
- Day one tends to pass without event, sometimes with a little extra gas. The strain's effects are read in stool counts and bowel habit across the following weeks.
- With regular use
- Improved gut health, fewer digestive issues, potential immune benefits, some evidence for reduced anxiety symptoms.
- How well tolerated
- Excellent. Nearly 90 years of commercial use. One of the safest and most studied probiotics.
- How it feels
- Subtle improvements in digestion and wellbeing over time. Many become daily users for life.
- The overlooked benefit
- It does not settle in permanently. Stool counts fall away within days to weeks of stopping, which is why the daily habit is the point rather than a finished course.
1,000,000,000 to 10,000,000,000 CFU a day is where Lactobacillus Casei Shirota works.
Source: ISAPP consensus statement 2019 + Ford 2014 meta-analysis
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Lactobacillus Casei Shirota has emerging evidence. Based on 1076+ studies.
- Survives to reach intestineExtensive acid survival research
- Improves gut healthNumerous clinical trials
- Immune modulationMultiple studies show immune benefits
- May reduce anxietySeveral studies show benefits, more research ongoing
Questions people ask about Lactobacillus Casei Shirota.
- What makes LcS special?
- First commercially successful probiotic (1935). Selected for acid survival and gut benefit. Over 100 published clinical studies.
- Is it only in Yakult?
- Primarily. Yakult owns the strain. Some capsule forms exist but the drink is the researched format.
- Does the research hold up?
- Yes. While company-funded, the quantity and quality of studies is impressive. Published in peer-reviewed journals with proper methodology.
- Why is the bottle so small?
- One bottle contains the optimal dose. Larger would be unnecessary calories and sugar. Daily consistency is key.
- Does it help with anxiety?
- Some studies show benefits for anxiety and stress symptoms. The gut-brain axis connection is real. Results vary.
- Is the sugar a problem?
- Each bottle has about 8-10g sugar. Consider in context of total diet. Yakult Light has less.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Inulin passes undigested to the colon where Lactobacillus casei ferments it to lactate. Providing the substrate with the strain is the classic synbiotic pairing.
Galactooligosaccharides are selectively used by lactobacilli and bifidobacteria, raising short chain fatty acid output and lowering luminal pH. That environment suits the delivered strain.
Lactobacilli export lactate that bifidobacteria and butyrate producers take up, linking the two genera in one fermentation chain. Blends exploit that complementarity.
Resistant starch escapes small intestinal amylase and is fermented in the colon, feeding lactate and butyrate producers. It extends fermentable substrate further along the bowel than short chain fructans.
PHGG ferments gradually across the whole colon rather than exhausting in the first segment. That gives a delivered Lactobacillus substrate beyond the proximal bowel.
By binding free iron, lactoferrin restrains iron-dependent gut organisms while lactobacilli, which need almost none, are unaffected. The net effect favours the delivered strain.
The lactate lactobacilli produce is converted to butyrate by other colonic species, and butyrate is the colonocyte's main fuel. Supplying it directly covers that step.
Carvacrol and thymol permeabilise bacterial membranes across genera, lactobacilli included. Co-dosing lowers the count of live organisms that reach the colon.
Berberine acts directly against a wide range of gut bacteria without sparing lactobacilli. Overlapping doses work against the strain.
Bentonite carries a charged layered surface that binds organic molecules and microbial cells in the lumen. Co-dosing reduces how much viable strain arrives downstream.
Chicory inulin is a longer-chain fructan fermented in the colon, favouring lactate and acetate producers including lactobacilli. It gives an ingested strain something to metabolise beyond what the diet happens to supply. Longer chains ferment further down the colon than FOS, which changes where the gas and the acids appear.
Pectin is a fermentable soluble fibre that colonic bacteria break down to short-chain fatty acids, and its viscosity also slows transit through the upper gut. Both effects change the environment an ingested strain passes through. This is fibre fermentation biochemistry, not a measured combination effect.
Psyllium is only partly fermented and works mainly through gel formation and water holding, which changes stool form and transit time. Transit time is one of the variables that determines how long an ingested strain remains in the colon. The interaction is physical, and its direction depends on where a person starts.
Multi-strain products combine lactobacilli that occupy overlapping niches, and probiotic effects are strain specific, so combining two strains adds their individual profiles rather than producing a new one. Where two strains compete for the same adhesion sites, the total is not simply the sum. Stated as formulation practice.
Lactobacilli produce lactate, and bifidobacteria and other colonic organisms consume lactate and acetate to make butyrate and propionate. That cross-feeding chain is well described in gut microbial ecology. Combining a lactate producer with lactate users targets the chain rather than one step.
S. boulardii is a yeast, so it is unaffected by antibacterial agents that would reduce a bacterial strain and it occupies a different niche. Products combine the two for that non-overlap. Yeast and bacterial counts are also assayed separately, which is a practical labelling point.
Glutamine is the primary fuel for small intestinal enterocytes, while butyrate from colonic fermentation fuels colonocytes. A formula pairing a live strain with glutamine is covering both segments of the intestinal lining. Cell metabolism, not a claim about any condition.
Zinc carnosine is used for mucosal integrity support and is combined with live cultures in gut-directed formulas on that basis. Zinc is also a cofactor in hundreds of enzymes, including those involved in epithelial turnover. The pairing is formulation logic plus established zinc biochemistry rather than a combination trial.
Vitamin D acts through a nuclear receptor expressed in intestinal epithelium and immune cells, where it influences antimicrobial peptide expression and tight junction proteins. A live strain acts on the luminal side of the same barrier. Two different levers on one interface, and both are described mechanistically rather than as an outcome.
Bovine colostrum supplies immunoglobulins, lactoferrin and oligosaccharides, and the oligosaccharide fraction is fermentable by lactobacilli and bifidobacteria. It also carries antibodies that bind bacteria, so it is not a neutral partner for a live culture. That two-way nature is why the row is enabling rather than simply additive.
A study of pre-sleep casein ingestion together with probiotic strains reported changes in anaerobic power and lower-body strength measures; casein and the strains were given together, so neither can be credited alone. Milk protein also buffers stomach acid, which is the mechanistic reason food-carried cultures survive gastric transit better. Read the performance finding as belonging to the combination.
Lactase splits lactose to glucose and galactose, and lactic acid bacteria carry their own beta-galactosidase activity that contributes to lactose breakdown in a fermented product. Both act on the same disaccharide. Because this strain is most often delivered in a fermented milk, the lactose context is worth stating plainly.
Gastric acid is the main barrier to a live culture reaching the intestine, and bicarbonate raises stomach pH. That is the same principle behind taking cultures with a meal or in a buffered matrix. It is an acid-chemistry mechanism; nothing here measures how many organisms survive as a result.
Activated charcoal adsorbs organic molecules and bacterial products indiscriminately in the gut lumen and is a poor companion for a live culture taken in the same dose. Separating them by several hours is the ordinary practice. The mechanism is physical adsorption, not any effect on the strain's biology once past it.
Some lactic acid bacteria carry glutamate decarboxylase and produce GABA from glutamate, which is the basis for the psychobiotic framing in the review literature. Supplying GABA directly and supplying a producer organism are two different routes, and orally administered GABA crosses into the brain poorly. The row is mechanistic and should not be read as a mood claim.
Slippery elm mucilage forms a viscous layer over mucosal surfaces and is partly fermentable, so it changes both the physical environment and the substrate available in the gut. It appears with live cultures in soothing gut formulas. The pairing is formulation practice supported by polysaccharide chemistry rather than a combination study.
Marshmallow root supplies mucilaginous polysaccharides with the same viscosity-and-substrate double role as slippery elm. Traditional use and polysaccharide chemistry are the basis; no measured interaction with a live culture exists. Stated at that confidence.
Guar gum, and particularly its partially hydrolysed form, is fermented in the colon to short-chain fatty acids and is well tolerated at moderate doses. It supplies substrate for the fermentation chain a lactate-producing strain feeds into. Fibre fermentation biochemistry, no combination effect claimed.
L. plantarum is another acid- and bile-tolerant lactobacillus used in multi-strain products alongside casei-group strains. Because probiotic effects do not transfer between strains, combining them adds two separately characterised profiles rather than amplifying one. That strain-specificity point is the whole reason to state it.
Nothing specific on file for Lactobacillus Casei Shirota. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Lactobacillus Casei Shirota actually does.
Lactobacillus casei Shirota is a single named strain, and probiotic effects are strain specific: findings from one Lactobacillus strain do not transfer to another, even within the same species.
The organism is a facultatively anaerobic, homofermentative-leaning lactic acid bacterium that ferments carbohydrate to lactate, lowering the pH of its immediate environment.
Acid and bile tolerance is what determines whether an ingested culture arrives in the intestine viable; gastric acid and bile salts are the two barriers every oral live culture has to cross.
Ingested probiotic strains transit rather than take up permanent residence. Detection in stool falls away within days to weeks of stopping intake, which is why effects depend on continued use.
Where Lactobacillus Casei Shirota comes from.
A stored sample of this exact strain is grown in tanks on a milk-based feed, with the acidity corrected as it goes because the bacteria sour their own broth. For the drink, the fermented liquid is bottled and kept cold. For capsules and sachets, the cells are spun out, mixed with sugars that protect them through freezing, dried under vacuum, then counted and identity-checked. More is put in than the label says, so the number still holds at the end of the shelf life.
Built by fermentation, the same way vitamin B12 and many amino acids are made at scale. Controlled conditions, consistent output.
Production starts from a banked, genetically characterised master culture of the named strain. The growth medium is typically a milk or milk-derived base with added carbohydrate, nitrogen sources and minerals; medium composition affects both cell yield and the residual matrix that travels with the cells.
The seed is scaled through successive fermenters under controlled temperature, pH and dissolved oxygen. Because the organism acidifies its own medium, pH is corrected during the run to keep growth going rather than letting the culture inhibit itself.
Cells are separated from spent medium by centrifugation or membrane filtration and washed. Beverage routes skip separation and carry the fermentation medium forward as the product.
The cell concentrate is blended with cryoprotectants such as sucrose, trehalose or a polyol, which stabilise membranes through the freezing and drying steps and largely determine how many cells survive them.
The concentrate is frozen and dried under vacuum, then milled and assayed for colony-forming units per gram by plate count or an equivalent method. Powder is overdosed against the label figure so the declared count still holds at end of shelf life, and strain identity is confirmed genetically.
Powder is blended with carriers and any prebiotic, then capsuled, sachet-filled or tabletted under controlled humidity, or the fermented base is bottled and refrigerated. Packaging with a moisture barrier and desiccant, plus a stated storage condition, is part of the format rather than an extra.
Labels rarely state whether a colony-forming-unit count is at manufacture or at end of shelf life, which is the difference that matters most. Per-strain counts inside a blend, the cryoprotectant used, and whether a preparation is live or heat-treated are also often unstated.
Getting Lactobacillus Casei Shirota from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- In adults carrying a cluster of metabolic risk markers, Lactobacillus casei Shirota did not shift overall gut bacterial composition or measured gut barrier markers compared with control.Randomised trial. Stadlbauer et al., 2015 (PloS one). PMID 26509793 ↗
- Three months of Lactobacillus casei Shirota in adults with a cluster of metabolic risk markers showed no detectable change in blood trimethylamine-N-oxide levels.Randomised trial. Tripolt et al., 2015 (Atherosclerosis). PMID 26188537 ↗
- In healthy men with lower natural killer cell activity, Lactobacillus casei Shirota did not produce a detectable change in the immune measures tracked.Randomised trial. Seifert et al., 2011 (The Journal of nutrition). PMID 21430250 ↗
- The authors argue the probiotic field has concentrated on Lactobacillus and Bifidobacterium at the expense of other candidate organisms, and restate that effects are strain specific rather than genus-level.Narrative review. Cappella C et al., 2026 (Gut Microbes). PMID 42219654 ↗
- Pooling trials in older adults, probiotic, prebiotic and synbiotic supplementation was associated with shifts in gut microbiota composition; composition is a marker and the pooled interventions used many different strains.Meta-analysis. Zhuang K et al., 2025 (Nutrition Journal). PMID 41023690 ↗
- A trial in healthy young adults assessed probiotic supplementation against perceived stress scores and bowel function; both outcomes are self-reported and the product was a probiotic preparation rather than this strain alone.Open-label trial. Noorwali EA et al., 2025 (Frontiers in Nutrition). PMID 41567324 ↗
- A randomised, double-blind, placebo-controlled study of a probiotic preparation for breath odour, reporting changes the authors link to glucose-related mechanisms; a specific probiotic product, not this strain in isolation.Randomised trial. Choi JH et al., 2026 (Probiotics and Antimicrobial Proteins). PMID 40512445 ↗
- A review of GABA-producing bacteria as candidate psychobiotics, describing glutamate decarboxylase activity in lactic acid bacteria and the gut-brain signalling routes proposed for it; mechanism, not demonstrated effect.Narrative review. Zielińska E et al., 2026 (International Journal of Molecular Sciences). PMID 42278495 ↗
- A review of dietary probiotics and aflatoxin B1, describing surface binding and sequestration of the toxin by lactic acid bacteria largely from in vitro and animal work.Narrative review. Choi D et al., 2025 (Toxins). PMID 41150183 ↗
- A systematic review of clinical studies on probiotics and dental health reporting effects on oral bacterial counts, with the authors noting heterogeneity across strains, doses and delivery formats.Systematic review. Inchingolo AD et al., 2025 (Frontiers in Oral Health). PMID 41409473 ↗
- A systematic review of probiotic supplementation and liver-related blood markers, inflammatory markers and gut microbiota composition; the readouts are markers, the strains pooled are mixed, and the population was clinical.Systematic review. Saadh MJ et al., 2025 (Frontiers in Nutrition). PMID 41487669 ↗
- A review of probiotic use in upper airway and sinus health, collating clinical studies across many strains; conclusions are strain-heterogeneous and cannot be assigned to a single organism.Narrative review. Azzi A et al., 2026 (Microorganisms). PMID 42197372 ↗
- An expert-opinion piece gathering the views of nephrology clinicians on multispecies probiotic use in adults with reduced kidney function; clinician opinion, which is the weakest form of evidence here and is labelled as such.Narrative review. Beniwal P et al., 2026 (Cureus). PMID 41769608 ↗
- Pre-sleep casein taken with probiotic strains was associated with higher anaerobic power and lower-body strength measures; casein and the strains were given together, so no component can be credited on its own.Open-label trial. Sadeghi R et al., 2025 (Journal of the International Society of Sports Nutrition). PMID 40353739 ↗
These are the studies our verdict leans on, chosen from the 1,340 we read for Lactobacillus Casei Shirota. The full linked list is below.
The studies, linked.
7 sources behind our Lactobacillus Casei Shirota verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialAn RCT in Nursing Homes: the Effect of a Probiotic Treatment With Lactobacillus Casei Shirota on Respiratory Morbidity After Influenza Vaccination of Elderly.ClinicalTrials.gov ↗PHASE4 · 737 participants · Completed
- Clinical trialDaily Intake of Lactobacillus Casei Shirota (LcS) Modulates Intestinal Permeability and Decreases Circulating Levels of Endotoxin That Associate With Both Cardiovascular and All-cause Mortality in Haemodialysis PatientsClinicalTrials.gov ↗NA · 60 participants · Completed
- Clinical trialEvaluation of the Effect of Yoghurt-type Drink on Symptoms of Subjects Suffering Seasonal Allergic Rhinitis (SAR) [Rhinitis 2]ClinicalTrials.gov ↗PHASE2 · 60 participants · Completed
- Clinical trialImmunological Effects of Continuous, Once a Day Use of Lactobacillus Casei Shirota on HIV-infected Patients on Suppressive Antiretroviral Treatment With Poor CD4+ T-cell RecoveryClinicalTrials.gov ↗PHASE2 · 48 participants · Completed
- Clinical trialNutritional Counseling Versus Nutritional Supplements for the Treatment of NASH - a Randomized Prospective, Open Label Pilot Study (Nuces NASH)ClinicalTrials.gov ↗PHASE2 · 42 participants · Completed
- Clinical trialDoes a Daily Dose of the Probiotic Lactobacillus Casei Shirota Prevent Acute Episodes of Diverticulitis (LACTOPRoD) - a Pilot StudyClinicalTrials.gov ↗NA · 26 participants · Completed
- Clinical trialSkin Inflammation in (Peri)Menopause: A Probiotic Intervention Proof of Concept Trial (SIPPI)ClinicalTrials.gov ↗NA · 30 participants · Recruiting
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.